A 200 mcg dose = 200 2,000 = 0.10 mL = 10 units
The Numbers That Matter: In the landmark SURMOUNT-5 trial published in the New England Journal of Medicine in May 2025, participants taking tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% with semaglutide
Potential Health Benefits Patients in medically supervised weight loss programs often see improvements in: Body weight and body composition Blood sugar and insulin sensitivity Blood pressure Cholesterol levels Energy levels Joint comfort and mobility Sleep quality Overall well-being Success is about more than weight its about better health and quality of life

GLP-1 Receptor Modulation Appetite Regulation and Glucose Control Activation of glucagon-like peptide-1 (GLP-1) receptors by GLP3 contributes to multiple metabolic effects observed in clinical studies[6]: Delayed gastric emptying , resulting in prolonged satiety and reduced meal size Suppression of appetite through actions on hypothalamic feeding centers Enhancement of glucose-stimulated insulin secretion from beta cells Inhibition of glucagon secretion from pancreatic alpha cells during hyperglycemic states Potential neuroprotective effects through central nervous system GLP-1 receptor engagement Phase 1b studies in humans with type 2 diabetes confirmed that GLP3 significantly delays gastric emptying, with effects persisting throughout the 12-week treatment period, suggesting limited tachyphylaxis development compared to some other GLP-1 receptor agonists[7]
Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, et al